शुभ दीपावलीDiwali offer: 3 months free on yearly plans · ends 11 NovSee plans
BSEBharat Parenterals Ltd· Pharmaceuticals & BiotechnologyHighPositive
Announced Thu, 24 Apr, 2025 · 15:37 IST

Update on Acquisition of Equity shares of varenyam Healthcare Pvt Ltd.

Listed-company acquisitionStrategic Transactions View source PDFExplain this filing

Price

Loading chart…

▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.

Price reaction

Awaiting price reaction for this filing.

AI summary

Bharat Parenterals Ltd (BPL) has completed the acquisition of Varenyam Healthcare Pvt Ltd (VHPL), making it a wholly owned subsidiary. The deal was executed via a share swap where BPL issued 3,51,255 equity shares on a preferential basis in exchange for 2,50,000 equity shares of VHPL. VHPL is a domestic player in pharmaceutical formulations for Anesthesia, Critical Care and Pain Management segments, with presence in major corporate hospitals. It is expected to contribute around ₹60 crore in revenue and ₹10 crore in EBITDA for FY2025-26. This marks the final step of a strategic restructuring announced in June 2024, which also included increasing BPL's stake in Innoxel Lifesciences from 51% to 55.9% and fully acquiring Varenyam Biolifesciences Pvt Ltd.

Likely market impact

Positive for shareholders as the acquisition expands BPL's commercial reach and product portfolio in high-value therapy areas, with meaningful revenue and EBITDA contribution expected from FY26. However, the share swap will result in slight equity dilution for existing shareholders.